JNJ's Zarnestra not approvable

Johnson & Johnson (JNJ) received a not approvable letter from FDA for its NDA for Zarnestra tipifarnib to treat elderly patients with newly diagnosed, poor-risk acute myeloid leukemia (AML). The compa...